New Market Research Report: Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
Fast Market Research announces the availability of the new GlobalData report, "Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016", on their comprehensive research portal
Boston, MA -- (SBWire) -- 11/08/2016 --Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
GlobalData's Medical Devices sector report, "Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Ovarian Cancer Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ovarian Cancer Diagnostic Tests pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Get More Details on this Report and a Full Table of Contents at Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
-Extensive coverage of the Ovarian Cancer Diagnostic Tests under development
-The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
-The report reviews the major players involved in the development of Ovarian Cancer Diagnostic Tests and list all their pipeline projects
-The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
-The report provides key clinical trial data of ongoing trials specific to pipeline products
-Recent developments in the segment / industry
Reasons to Get This Report
The report enables you to -
-Formulate significant competitor information, analysis, and insights to improve R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand important and diverse types of Ovarian Cancer Diagnostic Tests under development
-Develop market-entry and market expansion strategies
-Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
-In-depth analysis of the product's current stage of development, territory and estimated launch date
Companies Mentioned in this Report: A&G Pharmaceutical, Inc., Abnova Corporation, Almac Diagnostics Limited, ANGLE plc, AroCell AB, ArtemixRx, Augusta University, Aurelium BioPharma Inc., Avant Diagnostics, Inc., Axela Inc., Ayanda Biosystems S.A., Becton, Dickinson and Company, Bioindustry Park Silvano Fumero S.p.A., Ceres Nanosciences, Inc., Chronix Biomedical, Inc., Clarient, Inc., ClavGen Therapeutics LLC, Cleveland Diagnostics Inc., Clovis Oncology, Inc., Courtagen Life Sciences, Inc., Dako A/S, Dana-Farber Cancer Institute, Inc., Diazyme Laboratories, Eventus Diagnostics, Inc., Exiqon A/S, Exosomics Siena SpA, Fahy Gurteen UK Limited, Foundation Medicine, Inc., French National Institute of Health and Medical Research, Ganymed Pharmaceuticals AG, GeneNews Limited, Georgia Institute of Technology, GlycoZym, H. Lee Moffitt Cancer Center & Research Institute, Inc., Ikonisys, Inc., Inanovate (UK) Ltd., InterGenetics Incorporated, IV Diagnostics, Inc., John Hopkins University, KIYATEC Inc., Lab Discoveries Ltd., Laboratorios SALVAT S.A., Laboratory Corporation of America Holdings, Louisville Bioscience, Inc., MabCure Inc., MDNA Life Sciences, Inc., MDxHealth SA, Metabolon, Inc., Milagen, Inc., Myriad Genetics, Inc., Nanosphere, Inc., National University of Singapore, Novel Bio-spectrum Technologies, Inc., Olympia Diagnostics, Inc, Oncgnostics GmbH, Oncimmune (USA) LLC, Orion Genomics LLC, Oryzon Genomics SA, OTraces Inc., PeriRx LLC, Phenomenome Discoveries, Inc., Precision Biologics, Inc., Pronota NV, Protagen AG, Proteomika, Provista Diagnostics Inc., RiboMed Biotechnologies, Inc., Roche Diagnostics International Ltd., Rosetta Genomics Ltd, SomaLogic, Inc., Soricimed Biopharma Inc., Stage I Diagnostics, Inc., SurExam Life Science & Technology Co., Target Discovery, Inc., Teva Pharmaceutical Industries Ltd., The University of Adelaide, The University of Texas MD Anderson Cancer Center, Todos Medical, Transbiomed, SL, Universite de Montreal, University of South Florida, US Biomarkers, Inc., Vermillion, Inc., Vitatex Inc., Vitruvian Biomedical, Inc., Yale University
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Medical Devices research reports at Fast Market Research
You may also be interested in these related reports:
-Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
-Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
-Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
-Mammography Equipment - Medical Devices Pipeline Assessment, 2016
-Herpes Simplex Virus (HSV) Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
Media Relations Contact
Director of Marketing
Fast Market Research, Inc.
View this press release online at: http://rwire.com/734752